See you tomorrow, #ESOT_EPITA community!
The 15th EPITA Symposium begins tomorrow!.
Weโre looking forward to reconnecting, exchanging ideas and building new memories together.
Safe travels!
#EPITAsymposium
See you tomorrow, #ESOT_EPITA community!
The 15th EPITA Symposium begins tomorrow!.
Weโre looking forward to reconnecting, exchanging ideas and building new memories together.
Safe travels!
#EPITAsymposium
Our last work on AKI in diabetes link.springer.com/article/10.1...
Fonte: SpringerLink
Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study - eClinicalMedicine www.thelancet.com/journals/ecl...
Un grazie a Radio 24 per lโinvito a Il Cowboy e lo Stivale. Stimolante il confronto con Giuseppe Remuzzi e Andrew Spannaus su sanitร , obesitร e diabete: come abitudini, ambiente e politiche sanitarie plasmano la nostra salute.
www.radio24.ilsole24ore.com/programmi/Il...
#Diabete #Obesitร #Radio24
๐งฌ New case report in Acta Diabetologica: 10-year follow-up of islet transplantation in a patient with Wolfram syndrome.
Non-autoimmune, insulinopenic diabetes โ still responsive to beta-cell replacement.
Rethinking eligibility.
๐ doi.org/10.1007/s005...
#Diabetes #IsletTx
โPole poleโ โ I learned it climbing Kilimanjaro: slow, steady, with respect.
Now itโs the spirit of our new @AmJTransplant commentary on cautiously exploring IAT in IPMN patients.
Science moves best when it listens.
๐ doi.org/10.1016/j.aj...
#IAT #IPMN #PolePole
How should we assess graft function after islet autotransplantation?
A study from @SanRaffaeleMI compares 6 outcome classification systemsโincluding a data-driven model that better captures intermediate outcomes.
www.frontierspartnerships.org/journals/tra...
Can ฮฒ-cell replacement therapies for type 1 diabetes move beyond being a last resort?
In this new Diabetes article, we explore whatโs possible, whatโs needed, and what questions remain.
๐ doi.org/10.2337/dbi2...
#T1D #BetaCell #DiabetesResearch
#ESPEESE2025 has just wrapped up in Copenhagen!
We joined the Meet the Expert session on #Type1Diabetes therapies as guests from the DRI @SanRaffaeleMI.
The real challenge? Endocrine care that follows the patient across their whole life.
Easy to sayโฆ hard to doโฆ but not impossible.
#SanRaffaeleMI
Weโre excited to share our latest work published in the American Journal of Transplantation: Islet Autotransplantation in Focal Intraductal Papillary Mucinous Neoplasms: Evaluating Feasibility, Safety, and Metabolic Outcomes in Pancreatic Resection kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...
April 11, 2025 โ National Day for Organ Donation and Transplantation.
The breath becomes silence, but it doesnโt end.
Time just changes its body.
#OrganDonation #DonateLife #April11
www.facebook.com/share/v/1HSJ...
Weโve been exploring the potential of GLP-1 receptor agonists for treating Wolfram Syndrome, a rare form of diabetes.
#WolframSyndrome #GLP1 diabetesjournals.org/diabetes/art...
Just published www.frontierspartnerships.org/journals/tra...
Bringing new therapy to patients needs strong clinical trials and regulatory alignment. Europe is updating GCP guidelines (ICH E6(R3)) to boost efficiency while ensuring safety and transparency
๐ก Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop
A long story about our activity just published
Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy - The Lancet Diabetes & Endocrinology www.thelancet.com/journals/lan...